China FDA approves Clinical Trial Application for Adagloxad Simolenin Phase III Study

On 24 January 2017, OBI Pharma, Inc. (4174) received formal approval from the China Food and Drug Administration (CFDA) to conduct a proposed phase III clinical trial for Adagloxad Simolenin (OBI-822, formerly known as OPT-822)/OBI-821. This trial could be used in a future Biologics License Application (BLA) submission, subject to future amendment. OBI Pharma originally […]